Stocks · Healthcare · Medical - Pharmaceuticals
Citius Oncology, Inc. CTOR
$0.95 -3.06% Close, Oct 2, 2026 · NASDAQ · Market cap $88.3M
Expensive vs sectorHigh risk
Next earnings report: Dec 17, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 50.8% in a year.
- Over the past year the stock returned -51.8%, behind the S&P 500 by 66.8 percentage points.
- The stock is 50% below its highest close of the past year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- FCF growth (TTM, YoY)Bottom 2%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 12%
- Gross marginBottom 37%
- Operating marginBottom 15%
- Accruals (lower is better)Top 10%
- Interest coverBottom 13%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 15%
- Free-cash-flow yieldBottom 23%
- EBITDA / enterprise valueBottom 12%
- Sales / enterprise valueBottom 28%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 4%
- 6-month returnTop 28%
- 1-year return vs S&P 500Bottom 9%
- Distance from 52-week highBottom 19%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsBottom 20%
- Upside to consensus price targetTop 3%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 8%
- Maximum drawdown, 3 yearsBottom 1%
- Beta vs S&P 500 (lower is better)Bottom 3%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Gross margin | 53.1% | — | Bottom 37% | |
| Operating margin | -665.6% | — | Bottom 15% | |
| Net margin | -648.3% | — | — | |
| Free-cash-flow margin | -277.3% | — | — | |
| Return on invested capital | -88.7% | — | Bottom 12% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -23.5%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 0.0%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -86.4×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -44.89%
- Shareholder yield
- -44.89%
- Share count change, 1 year
- +50.8%
- Share count change, 3-year CAGR
- +6.2%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Jun 30, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 2 of 8
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- +1.8%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $6.00
- Target vs current price
- +531.6%
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 14, 2026 | -14.3% | +10.0% | -8.2% | +11.0% | — |
| May 15, 2026 | -2600.0% | -2.1% | -15.8% | -32.5% | -25.8% |
| Feb 13, 2026 | -50.0% | +3.4% | -1.7% | -31.2% | -23.4% |
| Dec 23, 2025 | +0.0% | +1.6% | -16.0% | -10.4% | -48.6% |
| Aug 12, 2025 | +46.7% | -1.7% | +1.7% | +10.5% | -8.7% |
| May 14, 2025 | -22.2% | -2.8% | -2.9% | +55.0% | +97.6% |
| Feb 14, 2025 | -50.0% | -2.3% | -8.6% | -42.7% | -30.2% |
| Dec 27, 2024 | +10.3% | +8.3% | +35.4% | +28.1% | -33.3% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 14, 2026 | -$0.08 | -$0.07 | -14.3% | $1.5M |
| May 15, 2026 | -$0.27 | -$0.01 | -2600.0% | $1.7M |
| Feb 13, 2026 | -$0.06 | -$0.04 | -50.0% | $3.9M |
| Dec 23, 2025 | -$0.06 | -$0.06 | +0.0% | — |
| Aug 12, 2025 | -$0.08 | -$0.15 | +46.7% | — |
| May 14, 2025 | -$0.11 | -$0.09 | -22.2% | — |
| Feb 14, 2025 | -$0.09 | -$0.06 | -50.0% | — |
| Dec 27, 2024 | -$0.07 | -$0.08 | +10.3% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 11.54× | — | — | Bottom 28% |
| Free-cash-flow yield | -22.31% | — | — | Bottom 23% |
| Earnings yield | -50.28% | — | — | Bottom 15% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 42
- Days above the 200-day average
- 13
- 50-day average slope (20 days)
- +18.4%
- 200-day average slope (20 days)
- -2.4%
- Distance from 50-day average
- +14.8%
- Distance from 200-day average
- +8.4%
- RSI (14)
- 50.8
- Relative volume
- 1.84×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 101.4%
- Volatility vs own 5-year history
- 43th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 2.83
- Correlation with S&P 500
- 0.31
- Current drawdown from 1-year high
- -49.7%
- Maximum drawdown, 3 years
- -98.8%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Aug 12, 2024 | Mar 30, 2026 | -98.8% | 408 days | Not yet recovered |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $88.3M
- EPS, diluted (TTM)
- -$0.48
- Revenue (TTM)
- $7.1M
- 52-week range
- $0.49 – $2.25
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| Operating income | -$9.7M | -$12.1M | -$20.6M | -$23.5M |
| Net income | -$10.9M | -$12.7M | -$21.1M | -$24.8M |
| EPS (diluted) | -$0.08 | -$0.19 | -$0.30 | -$0.34 |
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $3.9M | $1.7M | $1.5M |
| Net income | -$6.8M | -$6.7M | -$7.7M | -$5.4M | -$5.0M | -$5.5M | -$26.6M | -$8.9M |
| EPS (diluted) | -$0.10 | -$0.09 | -$0.11 | -$0.08 | -$0.06 | -$0.06 | -$0.27 | -$0.08 |
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Operating cash flow | -$47,968 | -$601,304 | $126,353 | -$5.5M |
| Capital expenditure | $0 | $4 | -$4 | -$4 |
| Free cash flow | -$47,970 | -$601,300 | $126,349 | -$5.5M |
| Dividends paid | $0 | $0 | $0 | $0 |
| Net share buybacks | $68.0M | $0 | $0 | $15.2M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $16.6M
- Total assets
- $112.1M
- Total liabilities
- $71.7M
- Total debt
- $10.2M
- Net debt
- -$6.4M
- Shareholders’ equity
- $40.4M
As of Jun 30, 2026 (filed Jun 30, 2026).
Short interest
- Shares sold short
- 509,543
- Days to cover
- 6.89
- Change vs previous report
- +8.7%
FINRA short interest, settlement date Sep 15, 2026.